Our results are consistent with a recently terminated IPF clinical trial, which demonstrated that monoclonal antibody inhibition of CCL2, a CCR4 chemokine ligand, showed no benefit and may even be detrimental (55). Here, CCR4 is linked to idiopathic pulmonary fibrosis.